Reuters logo
Nektar's opioid painkiller succeeds in key late-stage study
March 20, 2017 / 11:36 AM / 6 months ago

Nektar's opioid painkiller succeeds in key late-stage study

March 20 (Reuters) - Nektar Therapeutics said its experimental opioid, designed to achieve pain relief minus the high levels of euphoria that can lead to abuse and addiction with existing opioids, succeeded in a key late-stage study.

The drug, which by design reaches the brain slower than existing opioids to deter abuse, outperformed a placebo in over 600 patients with chronic lower back pain. (Reporting by Natalie Grover in Bengaluru; Editing by Anil D‘Silva)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below